Pharsight

Breztri Aerosphere generic

Breztri Aerosphere, owned by Astrazeneca Ab, is an authorized drug for market use since 23rd July, 2020. The drug consists of active ingredients such as Budesonide, Formoterol Fumarate, and Glycopyrrolate. Breztri Aerosphere is available in aerosol, metered;inhalation dosage forms. Currently, it holds 8 active patents, none of which have expired.

When will Breztri Aerosphere generic be available?

The generic version of Breztri Aerosphere is expected to be available after 5th October 2038, which marks the expiry of the drug's last patent, specifically patent US11331442 surrounding drug delivery systems and related methods.

Breztri Aerosphere uses

Breztri Aerosphere is mainly used in the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of this drug can be attributed to its active ingredient composition of Budesonide, Formoterol Fumarate, and Glycopyrrolate.

Breztri Aerosphere patent expiration

Breztri Aerosphere's last patent, US11331442 with its focus on drug delivery systems, is set to expire on 5th October 2038, paving the way for the potential release of Breztri Aerosphere generics. The other seven patents, including ones for compositions for pulmonary delivery, methods and systems for respiratory delivery etc., expire in 2030 and 2031 respectively. Below are the details of the patents:

Breztri Aerosphere dosage

Want to ask something?